Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 49

1.

Circulating tumor DNA shows variable clonal response of breast cancer during neoadjuvant chemotherapy.

Kim JY, Park D, Son DS, Nam SJ, Kim SW, Jung HH, Kim YJ, Park G, Park WY, Lee JE, Park YH.

Oncotarget. 2017 Sep 23;8(49):86423-86434. doi: 10.18632/oncotarget.21198. eCollection 2017 Oct 17.

2.

The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer.

Adamo B, Rita Ricciardi GR, Ieni A, Franchina T, Fazzari C, Sanò MV, Angelico G, Michele C, Tuccari G, Adamo V.

Oncotarget. 2017 Aug 16;8(44):76974-76986. doi: 10.18632/oncotarget.20293. eCollection 2017 Sep 29.

3.

Efficacy and toxicity profile of maintenance pemetrexed in patients with stage IV adenocarcinoma lung in Indian population.

Pankaj G, Ullas B, Doval DC, Parveen J, Amitabh UK, Dash PK, Akhil J, Agarwal M, Rajat B.

South Asian J Cancer. 2016 Oct-Dec;5(4):196-203. doi: 10.4103/2278-330X.195345.

4.

Neoadjuvant chemotherapy in breast cancers.

Masood S.

Womens Health (Lond). 2016 Sep;12(5):480-491. Review.

5.

A prospective comparison of ER, PR, Ki67 and gene expression in paired sequential core biopsies of primary, untreated breast cancer.

Hadad SM, Jordan LB, Roy PG, Purdie CA, Iwamoto T, Pusztai L, Moulder-Thompson SL, Thompson AM.

BMC Cancer. 2016 Sep 22;16(1):745.

6.
7.

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.

Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L.

Nat Rev Clin Oncol. 2016 Nov;13(11):674-690. doi: 10.1038/nrclinonc.2016.66. Epub 2016 May 17. Review.

8.

Exploring circulating micro-RNA in the neoadjuvant treatment of breast cancer.

Casey MC, Sweeney KJ, Brown JA, Kerin MJ.

Int J Cancer. 2016 Jul 1;139(1):12-22. doi: 10.1002/ijc.29985. Epub 2016 Jan 30. Review.

9.

Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer.

Guarneri V, Dieci MV, Frassoldati A, Maiorana A, Ficarra G, Bettelli S, Tagliafico E, Bicciato S, Generali DG, Cagossi K, Bisagni G, Sarti S, Musolino A, Ellis C, Crescenzo R, Conte P.

Oncologist. 2015 Sep;20(9):1001-10. doi: 10.1634/theoncologist.2015-0138. Epub 2015 Aug 5.

11.

Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients.

Ricciardi GR, Adamo B, Ieni A, Licata L, Cardia R, Ferraro G, Franchina T, Tuccari G, Adamo V.

PLoS One. 2015 Jun 3;10(6):e0128368. doi: 10.1371/journal.pone.0128368. eCollection 2015. Erratum in: PLoS One. 2015;10(7):e0132647.

12.

Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response.

Magbanua MJ, Wolf DM, Yau C, Davis SE, Crothers J, Au A, Haqq CM, Livasy C, Rugo HS; I-SPY 1 TRIAL Investigators, Esserman L, Park JW, van 't Veer LJ.

Breast Cancer Res. 2015 May 29;17:73. doi: 10.1186/s13058-015-0582-3.

13.

Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration.

Bossuyt V, Provenzano E, Symmans WF, Boughey JC, Coles C, Curigliano G, Dixon JM, Esserman LJ, Fastner G, Kuehn T, Peintinger F, von Minckwitz G, White J, Yang W, Badve S, Denkert C, MacGrogan G, Penault-Llorca F, Viale G, Cameron D; Breast International Group-North American Breast Cancer Group (BIG-NABCG) collaboration.

Ann Oncol. 2015 Jul;26(7):1280-91. doi: 10.1093/annonc/mdv161. Epub 2015 May 27. Review.

14.

EPMA position paper in cancer: current overview and future perspectives.

Grech G, Zhan X, Yoo BC, Bubnov R, Hagan S, Danesi R, Vittadini G, Desiderio DM.

EPMA J. 2015 Apr 15;6(1):9. doi: 10.1186/s13167-015-0030-6. eCollection 2015.

16.

Landscape of neoadjuvant therapy for breast cancer.

Haddad TC, Goetz MP.

Ann Surg Oncol. 2015 May;22(5):1408-15. doi: 10.1245/s10434-015-4405-7. Epub 2015 Mar 2. Review.

17.

Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.

Tan QX, Qin QH, Yang WP, Mo QG, Wei CY.

Int J Clin Exp Pathol. 2014 Sep 15;7(10):6862-70. eCollection 2014.

18.

Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information.

Inic Z, Zegarac M, Inic M, Markovic I, Kozomara Z, Djurisic I, Inic I, Pupic G, Jancic S.

Clin Med Insights Oncol. 2014 Sep 11;8:107-11. doi: 10.4137/CMO.S18006. eCollection 2014.

19.
20.

Evaluation of FLT-PET-CT as an imaging biomarker of proliferation in primary breast cancer.

Woolf DK, Beresford M, Li SP, Dowsett M, Sanghera B, Wong WL, Sonoda L, Detre S, Amin V, Ah-See ML, Miles D, Makris A.

Br J Cancer. 2014 Jun 10;110(12):2847-54. doi: 10.1038/bjc.2014.207. Epub 2014 May 15.

Supplemental Content

Support Center